Glaukos Corporation (GKOS) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Glaukos published the results on October 28, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Glaukos reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Q3 2026 SG&A includes a $14.1 million accrual for Glaukos' resolution agreement with the Regents of the University of California, which settled the final payment on certain U.S. patents and was paid in October 2026. Glaukos excludes it from non-GAAP results.
• Glaukos reports in thousands; figures here are in millions.

Source: Glaukos Q3 2026 results, October 28, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Glaukos splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Glaukos's U.S. Glaucoma revenue was $119 million in Q3 2026, up 47% from $80.8 million in Q3 2025, 56% of total revenue.
• Glaukos's International Glaucoma revenue was $33.4 million in Q3 2026, up 13% from $29.4 million in Q3 2025, 16% of total revenue.
• Glaukos's Corneal Health revenue was $59.0 million in Q3 2026, up 154% from $23.3 million in Q3 2025, 28% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Glaukos said:

“The company expects 2026 net sales to be in the range of $775 million to $785 million based on the latest foreign currency exchange rates.”

“The company expects preliminary 2027 net sales to be $1 billion based on the latest foreign currency exchange rates.”

“Glaukos now expects full-year 2026 global consolidated net sales of $775-$785 million, up from its previous guidance of $680-$700 million.”

Source: Glaukos Q3 2026 release, Oct 28, 2026.

This is the company's own guidance as of Oct 28, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the GKOS forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted net income (loss) per share, each as first reported in that quarter's release. Glaukos pre-announced preliminary Q4 2025 net sales on January 13, 2026; the Q4 row uses the full release of February 17, 2026.

We do not hold a confirmed date for Glaukos's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 28, 2026

Glaukos' net sales rose 58% to a record $211.0 million in Q3 2026, from $133.5 million a year earlier, on both a reported and constant currency basis. Glaucoma products were $152.0 million, of which $118.6 million came from the United States and $33.4 million from international markets, and Corneal Health was $59.0 million. (Glaukos Q3 2026 release, Oct 28, 2026; Glaukos Form 10-Q, Q3 2026, Oct 28, 2026)

Two launched pharmaceuticals drove the increase. U.S. Glaucoma grew 47% because of higher sales volume of iDose TR, an implant that delivers glaucoma drug therapy inside the eye and carries a higher net price than Glaukos' other products; iDose TR generated about $76 million in the quarter. Corneal Health grew 154%, including about $53 million of Epioxa, an incision-free keratoconus therapy approved by the FDA in 2025, partly offset by lower Photrexa sales as customers moved to Epioxa. (Glaukos Form 10-Q, Q3 2026, Oct 28, 2026; Glaukos Third Quarter 2026 in Review (Exhibit 99.2), Oct 28, 2026)

International Glaucoma rose 13% on a reported basis and 15% in constant currency, with volume growth led by the United Kingdom, France and Australia and partly offset by reimbursement challenges in Germany. Across both franchises, the United States was $174.8 million of net sales and international $36.2 million. (Glaukos Form 10-Q, Q3 2026, Oct 28, 2026; Glaukos Third Quarter 2026 in Review (Exhibit 99.2), Oct 28, 2026)

The launches have changed Glaukos' receivables. Accounts receivable rose to $150.0 million from $108.6 million at the end of 2025 because iDose TR and Epioxa carry extended payment terms, and one customer, Glaukos' specialty pharmacy, accounted for about 17% of net accounts receivable at September 30, 2026. (Glaukos Q3 2026 release, Oct 28, 2026; Glaukos Form 10-Q, Q3 2026, Oct 28, 2026)

Glaukos' GAAP diluted EPS was $0.03 in Q3 2026, against a loss of $0.28 a year earlier, on net income of $2.0 million. Non-GAAP diluted EPS was $0.47, against a loss of $0.16, on non-GAAP net income of $28.5 million. Income from operations was $0.8 million, against an operating loss of $16.4 million. (Glaukos Q3 2026 release, Oct 28, 2026)

The $26.5 million gap between GAAP and non-GAAP net income is mostly one item: $14.1 million of expenses for the resolution agreement with the Regents of the University of California. Glaukos also excluded $5.9 million of trade secrets and other litigation costs, $4.8 million of amortization of Avedro developed technology, $0.8 million of system integration costs and Mobius-related amortization and contingent consideration adjustments. The tax effect of the U.S. adjustments is $0 because Glaukos is in a U.S. taxable loss position. (Glaukos Q3 2026 release, Oct 28, 2026)

Gross margin was about 85%, up from about 78%, and non-GAAP gross margin about 88%, against about 84%. SG&A rose 58% to $130.9 million, and the 10-Q attributes $11.4 million of the $47.9 million increase to compensation and the $14.1 million accrual to the resolution agreement. R&D rose 26% to $48.1 million. Diluted weighted-average shares were 61,196 thousand, against 57,398 thousand a year earlier. (Glaukos Q3 2026 release, Oct 28, 2026; Glaukos Form 10-Q, Q3 2026, Oct 28, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Glaukos gives a net sales outlook in its release and nothing for earnings. With Q3 it raised its 2026 net sales guidance to $775 million to $785 million, from $680 million to $700 million, and introduced preliminary 2027 net sales guidance of $1 billion, both based on the latest foreign currency exchange rates. (Glaukos Q3 2026 release, Oct 28, 2026; Glaukos Third Quarter 2026 in Review (Exhibit 99.2), Oct 28, 2026)

Its quarterly review lists what the 2026 range tries to account for, including growing contributions from Epioxa, iDose TR and iStent infinite, uncertainties around five Medicare contractors' proposed local coverage determinations for iDose TR, and combo-cataract MIGS competition. (Glaukos Third Quarter 2026 in Review (Exhibit 99.2), Oct 28, 2026)

A consensus figure is the average of the models published by the analysts who cover Glaukos, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Glaukos's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning GKOS is on is GKOS a buy or a sell?, what analysts expect next is on the GKOS forecast, and what the company does is on the Glaukos Corporation (GKOS) stock page.

Every number on this page can be traced to a document Glaukos published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.